Literature DB >> 8793930

Intrinsic and acquired resistance to methotrexate in acute leukemia.

R Gorlick1, E Goker, T Trippett, M Waltham, D Banerjee, J R Bertino.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793930     DOI: 10.1056/NEJM199610033351408

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  44 in total

1.  Increased transport of pteridines compensates for mutations in the high affinity folate transporter and contributes to methotrexate resistance in the protozoan parasite Leishmania tarentolae.

Authors:  C Kündig; A Haimeur; D Légaré; B Papadopoulou; M Ouellette
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis.

Authors:  Sumit Majumdar; Meagan E Anderson; Christine R Xu; Tatyana V Yakovleva; Leo C Gu; Thomas R Malefyt; Teruna J Siahaan
Journal:  J Pharm Sci       Date:  2012-04-26       Impact factor: 3.534

Review 4.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

5.  Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.

Authors:  Peter D Cole; Richard A Drachtman; Angela K Smith; Sarah Cate; Richard A Larson; Douglas S Hawkins; John Holcenberg; Kara Kelly; Barton A Kamen
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

6.  PharmGKB summary: methotrexate pathway.

Authors:  Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

7.  Role of topical interferon alpha-2b in 'mitomycin-C-resistant' ocular surface squamous neoplasia: our preliminary findings.

Authors:  Manpreet Singh; Natasha Gautam; Manpreet Kaur
Journal:  Int Ophthalmol       Date:  2018-01-23       Impact factor: 2.031

8.  Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.

Authors:  Dhong Hyun Lee; Nils H Thoennissen; Catherine Goff; Gabriela B Iwanski; Charles Forscher; Ngan B Doan; Jonathan W Said; H Phillip Koeffler
Journal:  Cancer Lett       Date:  2011-03-26       Impact factor: 8.679

9.  mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL.

Authors:  Thanh-Trang T Vo; J Scott Lee; Duc Nguyen; Brandon Lui; William Pandori; Andrew Khaw; Sharmila Mallya; Mengrou Lu; Markus Müschen; Marina Konopleva; David A Fruman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

10.  CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.

Authors:  Yao Xue; Liucheng Rong; Na Tong; Meilin Wang; Zhengdong Zhang; Yongjun Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.